तुलना करने के लिए मीट्रिक्स | IMTX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMTXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.3x | −6.0x | −0.4x | |
PEG अनुपात | 0.01 | −0.07 | 0.00 | |
क़ीमत/बुक | 2.5x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 30.7x | 7.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 91.5% | 321.6% | 50.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.8% | 7.8% | अनलॉक करें |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.